{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:55:07Z","timestamp":1793757307255,"version":"4.6.1"},"reference-count":118,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:sec id=\"ab-jrv240033-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Testicular cancer is the most common solid malignancy among males aged 15 to 40 years in the US, with approximately 10\u202f000 new cases diagnosed each year. Between 90% and 95% of testicular cancers are germ cell tumors (GCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240033-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>The mean age at diagnosis for testicular cancer is 33 years. GCTs are categorized as seminomas and nonseminomatous GCTs (NSGCTs) based on their embryonic origins and path of differentiation. Risk factors include cryptorchidism, family history of testicular cancer, gonadal dysgenesis, infertility, cannabis use, and genetic conditions such as Klinefelter syndrome. The most common presenting symptom of testicular cancer is a painless testicular mass. History, physical examination, scrotal ultrasound, laboratory assessment of GCT-associated serum tumor markers (\u03b1-fetoprotein, \u03b2-human chorionic gonadotropin, and lactate dehydrogenase), and prompt referral to a urologist are indicated when testicular cancer is suspected. Early diagnosis and treatment, starting with a radical inguinal orchiectomy, are important to optimize outcomes. At diagnosis, GCT is stage I (localized to the testicle) in 70% to 75% of patients, stage II (metastatic only to the retroperitoneal lymph nodes) in 20%, and stage III (widely metastatic) in 10%. Treatment of GCTs is guided by histology, clinical staging, and risk classification, with 5-year survival rates of 99%, 92%, and 85% for those diagnosed at stages I, II, and III, respectively. Optimal treatment often involves a multidisciplinary team at high-volume, experienced medical centers and may include surveillance (serum tumor markers [\u03b1-fetoprotein, \u03b2-human chorionic gonadotropin, and lactate dehydrogenase] and imaging of the chest, abdomen, and pelvis), surgery (retroperitoneal lymph node dissection), chemotherapy, and\/or radiation. Treatment decisions should consider long-term survivorship concerns, including body image, fertility, hypogonadism, mental health, financial cost, adherence to follow-up, and late adverse effects of therapy such as cardiovascular disease, secondary malignancies, and potential psychosocial effects such as anxiety, depression, and social isolation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240033-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Testicular cancer is the most common solid malignancy in young men in the US, and 90% to 95% are GCTs. Patients with testicular GCT have a 5-year survival rate of 99%, 92%, and 85% for stages I, II, and III, respectively. Prompt diagnosis and treatment are important to optimize outcomes, and treatment decisions should balance oncologic control with survivorship concerns to minimize long-term adverse effects of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2024.27122","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:00:57Z","timestamp":1738580457000},"page":"793","source":"Crossref","is-referenced-by-count":101,"title":["Testicular Germ Cell Tumors"],"prefix":"10.1001","volume":"333","author":[{"given":"Nirmish","family":"Singla","sequence":"first","affiliation":[{"name":"Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland"},{"name":"Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[{"name":"Department of Urology and Radiation Medicine and Applied Sciences, University of California San Diego"},{"name":"Department of Urology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezra","family":"Baraban","sequence":"additional","affiliation":[{"name":"Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian D.","family":"Fankhauser","sequence":"additional","affiliation":[{"name":"Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser M. A.","family":"Ged","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"jrv240033r1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.33999","article-title":"Global patterns in testicular cancer incidence and mortality in 2020.","volume":"151","author":"Znaor","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"jrv240033r2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"jrv240033r3","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/cncr.30597","article-title":"Future of testicular germ cell tumor incidence in the United States: forecast through 2026.","volume":"123","author":"Ghazarian","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"jrv240033r4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00345-014-1361-y","article-title":"Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009.","volume":"33","author":"Nigam","year":"2015","journal-title":"World J Urol"},{"key":"jrv240033r5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fendo.2019.00408","article-title":"Testicular cancer: genes, environment, hormones.","volume":"10","author":"De Toni","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"jrv240033r6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3322\/caac.21819","article-title":"Testicular cancer in 2023: current status and recent progress.","volume":"74","author":"McHugh","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"jrv240033r7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1038\/sj.bjc.6601714","article-title":"Familial risk in testicular cancer as a clue to a heritable and environmental aetiology.","volume":"90","author":"Hemminki","year":"2004","journal-title":"Br J Cancer"},{"issue":"6","key":"jrv240033r8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/ije\/dyp287","article-title":"A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer\u2013experiences of the mother.","volume":"38","author":"Cook","year":"2009","journal-title":"Int J Epidemiol"},{"issue":"14","key":"jrv240033r9","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/jnci\/dji185","article-title":"Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men.","volume":"97","author":"Foss\u00e5","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"10029","key":"jrv240033r10","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(15)00991-5","article-title":"Testicular germ cell tumours.","volume":"387","author":"Rajpert-De Meyts","year":"2016","journal-title":"Lancet"},{"issue":"7183","key":"jrv240033r11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1136\/bmj.318.7183.559","article-title":"Risk of testicular cancer in subfertile men: case-control study.","volume":"318","author":"M\u00f8ller","year":"1999","journal-title":"BMJ"},{"issue":"9093","key":"jrv240033r12","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0140-6736(97)05526-8","article-title":"Risks of breast and testicular cancers in young adult twins in England and Wales: evidence on prenatal and genetic aetiology.","volume":"350","author":"Swerdlow","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"jrv240033r13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.1992.51","article-title":"Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis.","volume":"65","author":"Forman","year":"1992","journal-title":"Br J Cancer"},{"issue":"2","key":"jrv240033r14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2014.12.031","article-title":"Cancer risk in relatives of testicular cancer patients by histology type and age at diagnosis: a joint study from five Nordic countries.","volume":"68","author":"Kharazmi","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"jrv240033r15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1470-2045(04)01493-7","article-title":"Genetic predisposition to testicular germ-cell tumours.","volume":"5","author":"Lutke Holzik","year":"2004","journal-title":"Lancet Oncol"},{"issue":"11","key":"jrv240033r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16318","article-title":"Association between marijuana use and risk of cancer: a systematic review and meta-analysis.","volume":"2","author":"Ghasemiesfe","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"jrv240033r17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1158\/1055-9965.EPI-17-0428","article-title":"Cannabis use and incidence of testicular cancer: a 42-year follow-up of Swedish men between 1970 and 2011.","volume":"26","author":"Callaghan","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"jrv240033r18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/cncr.24159","article-title":"Association of marijuana use and the incidence of testicular germ cell tumors.","volume":"115","author":"Daling","year":"2009","journal-title":"Cancer"},{"issue":"21","key":"jrv240033r19","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1002\/cncr.27554","article-title":"Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk.","volume":"118","author":"Lacson","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"jrv240033r20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40360-021-00505-x","article-title":"Causal inference multiple imputation investigation of the impact of cannabinoids and other substances on ethnic differentials in US testicular cancer incidence.","volume":"22","author":"Reece","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"jrv240033r21","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/cncr.25499","article-title":"Marijuana use and testicular germ cell tumors.","volume":"117","author":"Trabert","year":"2011","journal-title":"Cancer"},{"key":"jrv240033r22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1186\/s12885-015-1905-6","article-title":"Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis.","volume":"15","author":"Gurney","year":"2015","journal-title":"BMC Cancer"},{"issue":"7","key":"jrv240033r23","doi-asserted-by":"publisher","first-page":"642.e1","DOI":"10.1016\/j.urolonc.2020.03.013","article-title":"Incident testicular cancer in relation to using marijuana and smoking tobacco: a systematic review and meta-analysis of epidemiologic studies.","volume":"38","author":"Song","year":"2020","journal-title":"Urol Oncol"},{"issue":"9","key":"jrv240033r24","doi-asserted-by":"publisher","first-page":"293.e1","DOI":"10.1016\/j.urolonc.2024.04.024","article-title":"Survival outcomes and molecular drivers of testicular cancer in hispanic men.","volume":"42","author":"Rezaee","year":"2024","journal-title":"Urol Oncol"},{"key":"jrv240033r25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.urology.2017.08.059","article-title":"Differences at presentation and treatment of testicular cancer in Hispanic men: institutional and national hospital-based analyses.","volume":"112","author":"Woldu","year":"2018","journal-title":"Urology"},{"issue":"19","key":"jrv240033r26","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1002\/cncr.33076","article-title":"Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital.","volume":"126","author":"Chertack","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"jrv240033r27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/j.1464-410X.2005.05504.x","article-title":"The changing presentation of germ cell tumours of the testis between 1983 and 2002.","volume":"95","author":"Powles","year":"2005","journal-title":"BJU Int"},{"issue":"4","key":"jrv240033r28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/gcc.2870010406","article-title":"Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification.","volume":"1","author":"Samaniego","year":"1990","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"jrv240033r29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/gcc.2870080405","article-title":"Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors.","volume":"8","author":"Rodriguez","year":"1993","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"jrv240033r30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/jnci\/86.5.349","article-title":"Clinical relevance of the i(12p) marker chromosome in germ cell tumors.","volume":"86","author":"Bosl","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"jrv240033r31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/MOU.0000000000000642","article-title":"Genetics of testicular germ cell tumors.","volume":"29","author":"Singla","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"7631","key":"jrv240033r32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature20596","article-title":"Genomic evolution and chemoresistance in germ-cell tumours.","volume":"540","author":"Taylor-Weiner","year":"2016","journal-title":"Nature"},{"key":"jrv240033r33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1096494","article-title":"Comprehensive characteristics of pathological subtypes in testicular germ cell tumor: gene expression, mutation and alternative splicing.","volume":"13","author":"Yao","year":"2023","journal-title":"Front Immunol"},{"issue":"8253","key":"jrv240033r34","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S0140-6736(81)91165-X","article-title":"Impact of delay in diagnosis on clinical stage of testicular cancer.","volume":"2","author":"Bosl","year":"1981","journal-title":"Lancet"},{"issue":"984","key":"jrv240033r35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/pgmj.2007.057992","article-title":"Testis cancer.","volume":"83","author":"Khan","year":"2007","journal-title":"Postgrad Med J"},{"issue":"4","key":"jrv240033r36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199707243370406","article-title":"Testicular germ-cell cancer.","volume":"337","author":"Bosl","year":"1997","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv240033r37","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/1097-0142(19851115)56:10<2534::AID-CNCR2820561036>3.0.CO;2-Q","article-title":"Gynecomastia in testicular cancer patients: prognostic and therapeutic implications.","volume":"56","author":"Tseng","year":"1985","journal-title":"Cancer"},{"key":"jrv240033r38","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.959573","article-title":"Characteristics of lung metastasis in testicular cancer: a large-scale population analysis based on propensity score matching.","volume":"9","author":"Guo","year":"2022","journal-title":"Front Surg"},{"issue":"2","key":"jrv240033r39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/JU.0000000000000318","article-title":"Diagnosis and treatment of early stage testicular cancer: AUA guideline.","volume":"202","author":"Stephenson","year":"2019","journal-title":"J Urol"},{"issue":"1","key":"jrv240033r40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7863\/jum.1985.4.1.13","article-title":"Diagnostic capabilities of high-resolution scrotal ultrasonography: prospective evaluation.","volume":"4","author":"Rifkin","year":"1985","journal-title":"J Ultrasound Med"},{"issue":"4","key":"jrv240033r41","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1148\/rg.2017160164","article-title":"Testicular seminoma and its mimics: from the radiologic pathology archives.","volume":"37","author":"Marko","year":"2017","journal-title":"Radiographics"},{"issue":"1","key":"jrv240033r42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jmrs.426","article-title":"Ultrasound morphological patterns of testicular tumours, correlation with histopathology.","volume":"68","author":"Necas","year":"2021","journal-title":"J Med Radiat Sci"},{"issue":"2","key":"jrv240033r43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.1997.15.2.594","article-title":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers.","volume":"15","author":"International Germ Cell Cancer Collaborative Group","year":"1997","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv240033r44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/088800101750059828","article-title":"Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood.","volume":"18","author":"Schneider","year":"2001","journal-title":"Pediatr Hematol Oncol"},{"issue":"7","key":"jrv240033r45","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.clinbiochem.2004.05.008","article-title":"Human chorionic gonadotropin in cancer.","volume":"37","author":"Stenman","year":"2004","journal-title":"Clin Biochem"},{"issue":"20","key":"jrv240033r46","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJM198011133032013","article-title":"Spurious rise in human chorionic gonadotropin induced by marihuana in patients with testicular cancer.","volume":"303","author":"Garnick","year":"1980","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv240033r47","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.2009.26.4481","article-title":"American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.","volume":"28","author":"Gilligan","year":"2010","journal-title":"J Clin Oncol"},{"key":"jrv240033r48","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5030349","article-title":"Serum tumour markers in testicular germ cell tumours: frequencies of elevated levels and extents of marker elevation are significantly associated with clinical parameters and with response to treatment.","volume":"2019","author":"Dieckmann","year":"2019","journal-title":"Biomed Res Int"},{"issue":"4","key":"jrv240033r49","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"issue":"14","key":"jrv240033r50","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG Update Consortium.","volume":"39","author":"Gillessen","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"jrv240033r51","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.20.03292","article-title":"Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-Update Consortium.","volume":"39","author":"Beyer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"jrv240033r52","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMra1407550","article-title":"Testicular cancer: discoveries and updates.","volume":"371","author":"Hanna","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240033r53","doi-asserted-by":"crossref","first-page":"14.e7","DOI":"10.1016\/j.urolonc.2017.08.024","article-title":"Impact of hospital case volume on testicular cancer outcomes and practice patterns.","volume":"36","author":"Woldu","year":"2018","journal-title":"Urol Oncol"},{"issue":"11","key":"jrv240033r54","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1200\/JCO.1996.14.11.2923","article-title":"Evaluation of long-term toxicity after chemotherapy for testicular cancer.","volume":"14","author":"Bokemeyer","year":"1996","journal-title":"J Clin Oncol"},{"issue":"14","key":"jrv240033r55","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jnci\/92.14.1165","article-title":"Treatment-associated leukemia following testicular cancer.","volume":"92","author":"Travis","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"jrv240033r56","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jnci\/dji278","article-title":"Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"jrv240033r57","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.","volume":"25","author":"van den Belt-Dusebout","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv240033r58","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","article-title":"Long-term toxicity of cisplatin in germ-cell tumor survivors.","volume":"28","author":"Chovanec","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"jrv240033r59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.1993.11.3.415","article-title":"Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.","volume":"11","author":"van Leeuwen","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv240033r60","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1200\/JCO.2004.05.205","article-title":"Mortality after cure of testicular seminoma.","volume":"22","author":"Zagars","year":"2004","journal-title":"J Clin Oncol"},{"issue":"22","key":"jrv240033r61","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2005.06.882","article-title":"Blood pressure and body mass index in long-term survivors of testicular cancer.","volume":"23","author":"Sagstuen","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv240033r62","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1200\/JCO.2016.70.3108","article-title":"Multi-institutional assessment of adverse health outcomes among north american testicular cancer survivors after modern cisplatin-based chemotherapy.","volume":"35","author":"Fung","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv240033r63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3322\/caac.21235","article-title":"Cancer treatment and survivorship statistics, 2014.","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"jrv240033r64","first-page":"395","article-title":"27-Year trends in incidence rates for testis cancer across a large statewide registry.","volume":"11","author":"Alzubaidi","year":"2023","journal-title":"Am J Clin Exp Urol"},{"issue":"6","key":"jrv240033r65","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.eururo.2017.12.030","article-title":"Non-risk-adapted surveillance for stage I testicular cancer: critical review and summary.","volume":"73","author":"Pierorazio","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"jrv240033r66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology Guidelines on Testicular Cancer: 2023 update.","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"jrv240033r67","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/JU.0000000000003694","article-title":"Diagnosis and treatment of early-stage testicular cancer: AUA guideline amendment 2023.","volume":"211","author":"Stephenson","year":"2024","journal-title":"J Urol"},{"issue":"3","key":"jrv240033r68","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bju.14967","article-title":"Lymphovascular invasion and presence of embryonal carcinoma as risk factors for occult metastatic disease in clinical stage I nonseminomatous germ cell tumour: a systematic review and meta-analysis.","volume":"125","author":"Blok","year":"2020","journal-title":"BJU Int"},{"issue":"3","key":"jrv240033r69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.euo.2023.10.014","article-title":"Prognostic factor risk groups for clinical stage I seminoma: an individual patient data analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.","volume":"7","author":"Boormans","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"jrv240033r70","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1159\/000530278","article-title":"Revisiting treatment protocols for stage I testicular seminoma: a SEER-based analysis.","volume":"107","author":"Elgenidy","year":"2023","journal-title":"Urol Int"},{"issue":"12","key":"jrv240033r71","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(03)01278-6","article-title":"Part I: testicular cancer\u2013management of early disease.","volume":"4","author":"Jones","year":"2003","journal-title":"Lancet Oncol"},{"issue":"3","key":"jrv240033r72","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ucl.2019.04.002","article-title":"Management of stage II germ cell tumors.","volume":"46","author":"Ghandour","year":"2019","journal-title":"Urol Clin North Am"},{"issue":"4","key":"jrv240033r73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOU.0000000000001099","article-title":"The role of primary retroperitoneal lymph node dissection in the treatment of stage II seminoma.","volume":"33","author":"Sigg","year":"2023","journal-title":"Curr Opin Urol"},{"issue":"11","key":"jrv240033r74","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/S1470-2045(22)00564-2","article-title":"Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01\/10): a single-arm, multicentre, phase 2 trial.","volume":"23","author":"Papachristofilou","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"jrv240033r75","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1159\/000020197","article-title":"RPLND or primary chemotherapy in clinical stage IIA\/B nonseminomatous germ cell tumors? results of a prospective multicenter trial including quality of life assessment.","volume":"37","author":"Weissbach","year":"2000","journal-title":"Eur Urol"},{"issue":"11","key":"jrv240033r76","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1200\/JCO.1995.13.11.2700","article-title":"Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.","volume":"13","author":"Motzer","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv240033r77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","article-title":"Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST).","volume":"84","author":"Hiester","year":"2023","journal-title":"Eur Urol"},{"issue":"16","key":"jrv240033r78","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.22.00624","article-title":"Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy.","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv240033r79","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1098-2388(199912)17:4<263::AID-SSU7>3.0.CO;2-6","article-title":"Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy.","volume":"17","author":"Baniel","year":"1999","journal-title":"Semin Surg Oncol"},{"issue":"7","key":"jrv240033r80","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.urolonc.2021.02.001","article-title":"Assessing quality of care in the diagnosis and treatment of early-stage testicular cancer: a critical review and summary.","volume":"39","author":"Huang","year":"2021","journal-title":"Urol Oncol"},{"issue":"2","key":"jrv240033r81","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.euo.2019.06.007","article-title":"Nationwide patterns of care for stage II nonseminomatous germ cell tumor of the testicle.","volume":"3","author":"Ghandour","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"jrv240033r82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"jrv240033r83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cam4.324","article-title":"Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.","volume":"4","author":"Chung","year":"2015","journal-title":"Cancer Med"},{"issue":"34","key":"jrv240033r84","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2013.53.5831","article-title":"Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort.","volume":"32","author":"Daugaard","year":"2014","journal-title":"J Clin Oncol"},{"key":"jrv240033r85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.euros.2023.08.008","article-title":"Prechemotherapy not preorchiectomy serum tumor markers accurately identify international germ cell cancer collaborative group prognostic groups in nonseminoma.","volume":"56","author":"Fankhauser","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"12","key":"jrv240033r86","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.6004\/jnccn.2019.0058","article-title":"Testicular cancer, version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"17","author":"Gilligan","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"jrv240033r87","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41416-018-0300-x","article-title":"Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.","volume":"119","author":"Watson","year":"2018","journal-title":"Br J Cancer"},{"issue":"4","key":"jrv240033r88","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.1998.16.4.1287","article-title":"Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.","volume":"16","author":"Nichols","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"jrv240033r89","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euo.2021.02.002","article-title":"Unilateral or bilateral retroperitoneal lymph node dissection in nonseminoma patients with postchemotherapy residual tumour? results from RETROP, a population-based mapping study by the Swedish Norwegian Testicular Cancer Group.","volume":"5","author":"Gerdtsson","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"jrv240033r90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdt425","article-title":"A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor.","volume":"25","author":"Ravi","year":"2014","journal-title":"Ann Oncol"},{"key":"jrv240033r91","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852681","article-title":"Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.","volume":"2014","author":"Treglia","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"jrv240033r92","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.juro.2007.10.054","article-title":"The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma.","volume":"179","author":"Hinz","year":"2008","journal-title":"J Urol"},{"issue":"33","key":"jrv240033r93","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2016.68.7798","article-title":"Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors.","volume":"34","author":"Bagrodia","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"jrv240033r94","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1200\/JCO.1995.13.5.1170","article-title":"Late relapse of testicular cancer.","volume":"13","author":"Baniel","year":"1995","journal-title":"J Clin Oncol"},{"issue":"6","key":"jrv240033r95","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/sj.bjc.6603014","article-title":"Late recurrences of germ cell malignancies: a population-based experience over three decades.","volume":"94","author":"Oldenburg","year":"2006","journal-title":"Br J Cancer"},{"issue":"34","key":"jrv240033r96","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.2007.15.7453","article-title":"Clinical outcome and predictors of survival in late relapse of germ cell tumor.","volume":"26","author":"Sharp","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"jrv240033r97","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1200\/JCO.1997.15.7.2559","article-title":"Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"issue":"7","key":"jrv240033r98","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.1998.16.7.2500","article-title":"Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.","volume":"16","author":"Loehrer","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10","key":"jrv240033r99","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.1996.14.10.2638","article-title":"High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables.","volume":"14","author":"Beyer","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv240033r100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv240033r101","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/annonc\/mdv131","article-title":"Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data.","volume":"26","author":"Capocaccia","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"jrv240033r102","doi-asserted-by":"crossref","first-page":"43.e17","DOI":"10.1016\/j.urolonc.2013.05.007","article-title":"Effect of the time from the presentation of symptoms to medical consultation on primary tumor size and survival in patients with testicular cancer: shift in the last 2 decades.","volume":"32","author":"Kobayashi","year":"2014","journal-title":"Urol Oncol"},{"issue":"6","key":"jrv240033r103","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1200\/JCO.23.01099","article-title":"Adolescent and young adult germ cell tumors: epidemiology, genomics, treatment, and survivorship.","volume":"42","author":"Travis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"jrv240033r104","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/pon.4596","article-title":"A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors.","volume":"27","author":"Smith","year":"2018","journal-title":"Psychooncology"},{"issue":"7","key":"jrv240033r105","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00520-004-0646-x","article-title":"Quality of life of survivors of testicular germ cell cancer: a review of the literature.","volume":"12","author":"Fleer","year":"2004","journal-title":"Support Care Cancer"},{"issue":"7","key":"jrv240033r106","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.20.02298","article-title":"Long-term mental health service utilization among survivors of testicular cancer: a population-based cohort study.","volume":"39","author":"Raphael","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"jrv240033r107","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107090","article-title":"Causes of death among patients with testicular cancer during the survivorship.","volume":"49","author":"Yang","year":"2023","journal-title":"Eur J Surg Oncol"},{"issue":"21","key":"jrv240033r108","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/jnci\/dji339","article-title":"Paternity following treatment for testicular cancer.","volume":"97","author":"Bryd\u00f8y","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"jrv240033r109","doi-asserted-by":"crossref","first-page":"483","DOI":"10.7326\/0003-4819-154-7-201104050-00006","article-title":"Screening for testicular cancer: US Preventive Services Task Force reaffirmation recommendation statement.","volume":"154","author":"US Preventive Services Task Force","year":"2011","journal-title":"Ann Intern Med"},{"issue":"5","key":"jrv240033r110","doi-asserted-by":"crossref","DOI":"10.1177\/15579883221130186","article-title":"A call to action to review the USPSTF\u2019s recommendation for testicular self-examination.","volume":"16","author":"Rovito","year":"2022","journal-title":"Am J Mens Health"},{"issue":"3","key":"jrv240033r111","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.juro.2010.11.007","article-title":"Terminology and details of the diagnostic process for testis cancer.","volume":"185","author":"Connolly","year":"2011","journal-title":"J Urol"},{"issue":"6","key":"jrv240033r112","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.eururo.2007.06.003","article-title":"Impact of diagnostic delay in testis cancer: results of a large population-based study.","volume":"52","author":"Huyghe","year":"2007","journal-title":"Eur Urol"},{"issue":"8","key":"jrv240033r113","doi-asserted-by":"crossref","first-page":"792","DOI":"10.6004\/jnccn.2023.0041","article-title":"NCCN Guidelines insights: survivorship, version 1.2023.","volume":"21","author":"Sanft","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"jrv240033r114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euros.2021.02.003","article-title":"Serum small RNA sequencing and miR-375 assay do not identify the presence of pure teratoma at postchemotherapy retroperitoneal lymph node dissection.","volume":"26","author":"Lafin","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"jrv240033r115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JU.0000000000001337","article-title":"Real-world application of pre-orchiectomy miR-371a-3p test in testicular germ cell tumor management.","volume":"205","author":"Badia","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"jrv240033r116","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2019.10.005","article-title":"Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-na\u00efve patients undergoing retroperitoneal lymph node dissection.","volume":"77","author":"Lafin","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"jrv240033r117","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.eururo.2019.06.010","article-title":"MicroRNAs: turning the tide in testicular cancer.","volume":"76","author":"Singla","year":"2019","journal-title":"Eur Urol"},{"issue":"16","key":"jrv240033r118","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of microRNA-371a-3p (M371 Test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study.","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2829847\/jama_singla_2025_rv_240033_1741036065.09842.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:03:49Z","timestamp":1741086229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2829847"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":118,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.27122","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,4]]}}}